Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Intra-Cellular Ther (NQ: ITCI )

91.29 +0.78 (+0.86%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 8, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Intra-Cellular Ther

< Previous 1 2 3 4 5 Next >
The Week Ahead In Biotech (Dec. 12-18): Hematology Conference Presentations, FDA Decisions For Calliditas, Argenx, Intra-Cellular & Eagle Pharma And More
Biotech stocks closed out the week ending Dec. 10 with modest losses as investors moved money out of defensives and into risky bets amid the broader market rebound. Multiple... 
Via Benzinga
Exposures Product Safety
Attention Biotech Investors: Mark Your Calendar For December PDUFA Dates
A majority of verdicts handed down by the FDA in November were positive. Three new molecular entities were approved during the month, taking the total number of NME approvals for... 
Via Benzinga
Exposures Product Safety
Looking Into Intra-Cellular Therapies's Return On Capital Employed
Benzinga Pro data, Intra-Cellular Therapies (NASDAQ:ITCI) reported Q3 sales of $22.21 million. Earnings fell to a loss of $77.32 million, resulting in a 11.83% decrease from last... 
Via Benzinga
Intra-Cellular Therapies inc (ITCI) Q3 2021 Earnings Call Transcript
ITCI earnings call for the period ending September 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight
Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader markets. Earnings continued to flow in,... 
Via Benzinga
Exposures Product Safety
Earnings Scheduled For May 10, 2021
Companies Reporting Before The Bell • Revlon (NYSE:REV) is likely to report earnings for its first quarter. • Bluegreen Vacations (NYSE:BVH) is expected to report... 
Via Benzinga
Intra-Cellular Therapies: Q3 Earnings Insights
Intra-Cellular Therapies (NASDAQ:ITCI) reported its Q3 earnings results on Tuesday, November 9, 2021 at 08:00 AM. Here's what investors need to know about the... 
Via Benzinga
Two Trillion-Dollar Industries Being Transformed By Tech
FN Media Group Presents Oilprice.com Market Commentary London – October 20, 2021 – Big money is pouring into two disruptive segments in two of the world’s biggest industries – healthcare and energy.... 
Via FinancialNewsMedia
Benzinga's Top Ratings Upgrades, Downgrades For September 23, 2021
Upgrades Barclays upgraded the previous rating for Warner Music Group Corp (NASDAQ: 
Via Benzinga
Looking Into Intra-Cellular Therapies's Return On Capital Employed
Intra-Cellular Therapies (NASDAQ:ITCI) brought in sales totaling $20.05 million during Q2 according to data provided by Benzinga Pro. However, earnings decreased 29.92%, resulting... 
Via Benzinga
Why Intra-Cellular Therapies Was Weak This Week
The company's second-quarter net loss was a bit deeper than analysts expected. 
Via The Motley Fool
Intra-Cellular Therapies inc (ITCI) Q2 2021 Earnings Call Transcript
ITCI earnings call for the period ending June 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Intra-Cellular Therapies: Q2 Earnings Insights
Shares of Intra-Cellular Therapies (NASDAQ:ITCI) were unchanged after the company reported Q2 results. Quarterly Results Earnings per share rose 11.46% over the past year... 
Via Benzinga
Pandemic Fallout: 6 Mental Health Stocks To Watch
One of the most devastating long-term impacts of the COVID-19 pandemic may be the toll it has taken on people’s mental health. The next globa... 
Via Benzinga
Exposures COVID-19
Looking Into Intra-Cellular Therapies's Return On Capital Employed
During Q1, Intra-Cellular Therapies (NASDAQ:ITCI) brought in sales totaling $15.88 million. However, earnings decreased 13.23%, resulting in a loss of $53.22 million. In Q4, Intra... 
Via Benzinga
Earnings Scheduled For August 9, 2021
Companies Reporting Before The Bell • Privia Health Group (NASDAQ:PRVA) is projected to report quarterly loss at $1.57 per share on revenue of $215.17 million. •... 
Via Benzinga
The Daily Biotech Pulse: Lilly Spikes On Alzheimer's Drug Regulatory Filing Plan, Applied Genetics, Arcus Issue Data Readouts, Adcom Test Awaits Incyte, Monte Rosa Prices IPO
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 23) AngioDynamics, Inc. (NASDAQ... 
Via Benzinga
The Daily Biotech Pulse: Regeneron COVID-19 Antibody Cocktail Data, FDA Nod For Mallinckrodt, Molecular Partners IPO
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 15) Apellis Pharmaceuticals,... 
Via Benzinga
Exposures COVID-19 Product Safety
The Daily Biotech Pulse: Gemini Sinks On Data, Amgen's Migraine Drug Approved In Japan, Liver Congress Gets Underway
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 22) AngioDynamics, Inc. (NASDAQ... 
Via Benzinga
Biotechs Ready To Roar
The biggest event last week was the FDA decision to approve Biogen's drug aducanumab, a treatment for Alzheimer's disease. The decision will reverberate across the industry and the healthcare sector... 
Via Talk Markets
Exposures Product Safety
Stocks That Hit 52-Week Highs On Tuesday
Before 10 a.m. ET Tuesday, 59 stocks made new 52-week highs. Intriguing Points: Microsoft (NASDAQ:MSFT) was the company with the largest market cap to set a new 52-week... 
Via Benzinga
The Daily Biotech Pulse: Vertex Shelves Mid-Stage Study, Precigen & Novan Jump On Data, Hematology Conference, Janux Debuts
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 10) Alexion Pharmaceuticals,... 
Via Benzinga
The Daily Biotech Pulse: Sanofi, Translate Bio Start Early Stage Seasonal Flu Vaccine Study, Dr. Reddy's Launches Generic Vascepa, Halozyme Strikes Licensing Deal
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 21) Agios Pharmaceuticals, Inc... 
Via Benzinga
The Daily Biotech Pulse: US To Procure 500M Pfizer-BioNTech Vaccine Doses For Donation, Verona Out-Licenses COPD Drug, Nautilus Lists Through SPAC Deal
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 9) Aethlon Medical, Inc. (... 
Via Benzinga
The Daily Biotech Pulse: Hookipa, PDS Biotech Report Positive Data, Ironwood CFO To Depart, Decision Day For Vertex
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 7) Agios Pharmaceuticals, Inc... 
Via Benzinga
Looking Into Intra-Cellular Therapies's Return On Capital Employed
During Q1, Intra-Cellular Therapies (NASDAQ:ITCI) brought in sales totaling $15.88 million. However, earnings decreased 13.23%, resulting in a loss of $53.22 million. In Q4, Intra... 
Via Benzinga
Intra-Cellular Therapies Inc (ITCI) Q1 2021 Earnings Call Transcript
ITCI earnings call for the period ending March 31, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Recap: Intra-Cellular Therapies Q1 Earnings
Shares of Intra-Cellular Therapies (NASDAQ:ITCI) were unchanged after the company reported Q1 results. Quarterly Results Earnings per share rose 10.96% over the past year... 
Via Benzinga
The Daily Biotech Pulse: Pfizer In Vaccine Supply Talks With India, Provention In Focus Ahead Of Briefing Doc, NeuroRx To List Via SPAC Deal
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 24) Bristol-Myers Squibb Company... 
Via Benzinga
The Week Ahead In Biotech (May 9-15): Heron, Apellis FDA Decisions, Presentations and Earnings
Biotech stocks came under pressure in the week ended May 7 as traders digested a slew of earnings news flow and a handful of clinical trial readouts. COVID-19 vaccine stocks came... 
Via Benzinga
Exposures COVID-19 Product Safety
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.